Tom McCarthy

Tom is Chief Executive Officer & Managing Director of Spinifex Pharmaceuticals. He has over 16 years experience in drug discovery and development and has been responsible for a variety of drug development programs under Investigation New Drug applications (IND) with the United States Food and Drug Administration (FDA) and other regulatory authorities. In addition to his role as CEO, Tom also oversees the CMC program for EMA401 and, with Alan Naylor (Spinifex SAB member), directs the AT2 receptor antagonist medicinal chemistry program. Tom’s prior positions include Vice President, Drug Development at Starpharma Pty Ltd where he was responsible for Starpharma’s projects from lead candidate optimization/selection through to IND submission and clinical trials. In this role he managed the development for SPL7013 Gel (VivaGel™) and was responsible for securing in excess of US$25M of United States National Institutes of Health (NIH) funding for Starpharma’s drug development programs. Tom completed a Bachelor of Science (Honours) degree and a Ph.D. in medicinal chemistry at Monash University in 1989 and 1993 respectively and has completed post-doctoral training at the University of Oxford.